2025-10-14 - Analysis Report
Okay, here's an analysis of Tempus AI Inc. (TEM) based on the data you provided.

## Tempus AI Inc. (TEM) Analysis

**Company Overview:** Tempus AI Inc. is a technology company that is building the world’s largest library of clinical and molecular data and an operating system to make that data accessible and useful.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 51.35%
*   **VOO Cumulative Return:** 25.90%
*   **Absolute Divergence:** 28.7
*   **Relative Divergence:** 60.3

**Analysis:** TEM has significantly outperformed the S&P 500. The relative divergence of 60.3 suggests that while TEM's performance is strong, it's not at the extreme upper end of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 51.0% | 70.1% | 26.0% | 0.3 | 16.4 |

*   **CAGR (Compound Annual Growth Rate):** 51.0% - High growth rate.
*   **MDD (Maximum Drawdown):** 70.1% - Significant risk/volatility.
*   **Alpha:** 26.0% - Indicates outperformance relative to the market (risk-adjusted).
*   **Beta:** 0.3 - TEM's price is theoretically 30% as volatile as the market.
*   **Cap(B):** 16.4 - TEM's market capitalization is $16.4 billion.

**Analysis:** The data suggests a high-growth stock with substantial volatility, outperforming the market.

### 2. Recent Price Action

*   **Current Price:** $94.47
*   **Previous Close:** $96.39
*   **Change:** -1.99
*   **5-day Moving Average:** $97.02
*   **20-day Moving Average:** $87.90
*   **60-day Moving Average:** $76.01

**Analysis:** The stock is currently trading below its 5-day moving average, suggesting some short-term downward pressure. The price is above the 20-day and 60-day moving averages, indicating an overall upward trend in the medium and longer term. The recent price decrease of -1.99 reflects a slight short-term dip.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 67.41 - Approaching overbought territory.
*   **PPO (Percentage Price Oscillator):** 0.74 - Indicates positive momentum.
*   **Hybrid Signal:** Buy 100% (Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** 11.4 (+) - Short-term increase in outperformance.
*   **Expected Return (%):** NaN - No data provided, can't comment.

**Analysis:** The MRI suggests a medium investment recommendation. The RSI nearing 70 suggests the stock is approaching overbought conditions, which could lead to a pullback. The PPO indicates positive momentum. Recent price decreased by -1.99 suggests a slight short-term dip.

### 4. Recent News & Significant Events

*   **Positive Catalysts:**
    *   ARPA-H Adaptive Cancer Program Role
    *   FDA Clearance for xR IVD Device
*   **Valuation Concerns:**
    *   Assessing Valuation as Investor Interest Grows Without Clear Catalysts
* **Broader Industry Trends:**
    *   Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

**Analysis:** Recent news indicates positive catalysts (ARPA-H selection, FDA clearance) that could drive the stock price higher. However, there's also concern about valuation, suggesting that investor sentiment is growing without firm fundamental catalysts.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (2.15 on a 1-5 scale)
*   **Target Price:** $77.55 (average), $100 (high), $60 (low)

**Analysis:** Analyst consensus is generally positive. The average target price ($77.55) is below the current price, suggesting that some analysts may believe the stock is currently overvalued.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15     |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59     |

**Analysis:** Tempus AI is not yet profitable. The company has consistently reported negative EPS. Recent EPS figures have generally been slightly better than expected, which could be a positive sign. The EPS of 2024-08-06 is particularly bad, at -0.63.

### 6. Financial Information:

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.31B  | 61.99%        |
| 2025-03-31   | $0.26B  | 60.69%        |
| 2024-12-31   | $0.20B  | 60.83%        |
| 2024-09-30   | $0.18B  | 58.50%        |
| 2024-06-30   | $0.17B  | 45.50%        |

Capital and Profitability:

| Quarter      | Equity  | ROE        |
|--------------|---------|------------|
| 2025-06-30   | $0.31B  | -13.84%    |
| 2025-03-31   | $0.33B  | -20.86%    |
| 2024-12-31   | $0.06B  | -23.10%    |
| 2024-09-30   | $0.05B  | -141.16%   |
| 2024-06-30   | $0.10B  | -562.04%   |

**Analysis:** Revenue is growing steadily, and profit margins are high and increasing, which are positive signs. However, the company has negative ROE (Return on Equity), indicating unprofitability relative to equity.

### 7. Overall Summary

**Strengths:**

*   Significant outperformance vs. S&P 500
*   High growth rate (CAGR)
*   Positive momentum (PPO)
*   Analyst consensus is a buy
*   Revenue growth and high profit margins
*   Recent positive catalysts (ARPA-H, FDA clearance)
*   Relatively low Beta

**Weaknesses:**

*   High volatility (MDD)
*   RSI approaching overbought
*   Negative EPS and ROE (currently unprofitable)
*   Valuation concerns
*   Average analyst target price below current price

**Conclusion:**

Tempus AI shows promise with strong revenue growth, high profit margins, and exciting developments in its core business. However, investors should be aware of the high volatility, current unprofitability, and valuation concerns. A thorough assessment of the company's future profitability and ability to justify its valuation is crucial before making an investment decision.

